MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET

H. Endo, H. Shimada, Y. Kimura, M. Ichise, M. Ono, H. Shinotoh, F. Niwa, S. Kitamura, K. Takahata, S. Hirano, S. Koga, D.W. Dickson, N. Sahara, M. Yamada, M. Higuchi, T. Toda, T. Suhara (Chiba, Japan)

Meeting: 2016 International Congress

Abstract Number: 1172

Keywords: Aging, Neurofibrillary tangles(NFT), Tauopathies

Session Information

Date: Wednesday, June 22, 2016

Session Title: Neuroimaging (non-PD)

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: This study was aimed at evaluating pathological tau accumulations in the brains of patients with progressive supranuclear palsy (PSP) and young and old healthy subjects using positron emission topography (PET) and a specific radioligand, [11C]PBB3.

Background: Deposition of tau proteins is critically implicated in PSP. We investigated distribution of PET-detectable tau lesions in PSP patients and its association with the disease progression.

Methods: Fourteen PSP patients (age ± SD: 71.9 ± 7.7 y), 11 young and 13 old healthy subjects (34.4 ± 7.0 y and 68.0 ± 4.3 y, respectively) underwent clinical evaluations, magnetic resonance scans, and [11C]PBB3-PET scans. All participants had negative amyloid β peptide (Aβ) scans. We investigated [11C]PBB3 binding in gray matter (GM) and white matter (WM) regions by generating parametric images of binding potential (BP*ND). Additionally, we evaluated PSP brain tissue samples by triple staining including PBB3 fluorescent, AT8 immunohistochemical and Gallyas silver staining.

Results: PSP patients showed significantly elevated BP*ND in the whole GM and WM compared with young and old healthy subjects. Notably, BP*ND values of [11C]PBB3 in WM of the frontoparietal cortices were significantly correlated with the motor symptoms of PSP patients (p < 0.05). Histochemically, PBB3 fluorescently labeled numerous neuritic and glial tau inclusions in PSP frontal GM and WM, which were also stained with phospho-tau antibody and Gallyas silver impregnation.

Conclusions: In clear distinction from Alzheimer’s disease cases, PSP patients exhibited deposition of PBB3(+) tau in both GM and WM. Regional radioligand binding provided an objective measure of the disease severity, potentially serving for therapeutic assessments.

H. Shimada, M. Higuchi, and T. Suhara hold a patent on compounds including PBB3 (PCT/JP2012/083286).

To cite this abstract in AMA style:

H. Endo, H. Shimada, Y. Kimura, M. Ichise, M. Ono, H. Shinotoh, F. Niwa, S. Kitamura, K. Takahata, S. Hirano, S. Koga, D.W. Dickson, N. Sahara, M. Yamada, M. Higuchi, T. Toda, T. Suhara. In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/in-vivo-evaluation-of-tau-pathologies-in-patient-with-progressive-supranuclear-palsy-and-healthy-subjects-with-11cpbb3-pet/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/in-vivo-evaluation-of-tau-pathologies-in-patient-with-progressive-supranuclear-palsy-and-healthy-subjects-with-11cpbb3-pet/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley